Exact Sciences may be overvalued with mixed growth prospects, but the 17 analysts following the company give it an average rating of buy. The analysts have set target prices ranging from $55.0 to $95.0 per share, for an average of $76.24. At today's price of $64.57, Exact Sciences is trading -15.31% away from its average target price, suggesting there is an analyst consensus of some upside potential.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Based in Madison, WI, the mid-cap Health Care company has 6,300 full time employees. Exact Sciences has not offered a dividend during the last year.
Exact Sciences does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at -1.87. The average P/E ratio for the Health Care sector is 24.45. On the other hand, the market is undervaluing Exact Sciences in terms of its net assets because its P/B ratio is 3.8. In comparison, the sector average is 4.16.
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (MM) | $876 | $1,491 | $1,767 | $2,084 |
| Revenue Growth | n/a | 70.19% | 18.49% | 17.95% |
| Gross Margins | 75.3% | 76.2% | 74.0% | 72.4% |
| Gross Margins Growth | n/a | 1.2% | -2.89% | -2.16% |
| Operating Margins | -26.7% | -37.4% | -47.3% | -27.7% |
| Operating Margins Growth | n/a | -40.07% | -26.47% | 41.44% |
| Net Margins | -9.59% | -56.9% | -33.71% | -29.91% |
| Net Margins Growth | n/a | -493.33% | 40.76% | 11.27% |
| Earnings Per Share | -$0.64 | -$5.61 | -$3.48 | -$3.48 |
| EPS Growth | n/a | -776.56% | 37.97% | 0.0% |
| Diluted Shares (MM) | 131 | 151 | 171 | 179 |
| Free Cash Flow (MM) | -$287 | $72 | -$238 | -$438 |
| FCF Growth | n/a | 125.15% | -429.96% | -84.04% |
| Capital Expenditures (MM) | -$172 | -$64 | -$136 | -$214 |
| LT Debt to Equity | 0.36 | 0.48 | 0.64 | 0.73 |
